-
-
Finance -
Finance -
Finance -
Finance
Editor’s Choice
Editor's Choice
First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes
ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug […]
Editor's Choice
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study showed that […]
Editor's Choice
The integral role of the microbiome in a post-pandemic world
At the beginning of 2020, I said to the Seventure team, that this would be the ‘Year of the Microbiome’.I still believe this will be true even in a COVID-19 world when our lives have […]
In Case you Missed it:
Reports
The Microbiome Biotech Landscape: An Analysis of the Pharmaceutical Pipeline
This content is restricted.
Reports
Microbiome after coronavirus: Investing in the power of microbes
This content is restricted.
Finance
Vedanta Biosciences Awarded Up to $76.9 Million to Advance Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria, today announced it has been awarded funding of $7.4 million, with the potential […]
Finance
Locus Biosciences signs contract with BARDA to advance $144 million precision medicine program to develop LBP-EC01, a crPhage™ product
Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli […]
Finance
Arranta Bio Announces Mechanical Completion of Commercial-Ready Capacity for advanced biologics
Arranta Bio (“Arranta”), a leading microbiome contract development and manufacturing organization (CDMO), today announced the mechanical completion of GMP suites at its Watertown, MA commercial-ready facility. Arranta is investing more than $100M in 2020 to […]
